- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | Moss Genomics Inc: Moss Genomics appoints director, fractional CFO | 2 | Stockwatch | ||
| 26.02. | Moss Genomics Inc. Announces Leadership Changes | 118 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to... ► Artikel lesen | |
| 25.02. | Moss Genomics Inc: Moss Genomics doubles down on blockchain, ethereum | 1 | Stockwatch | ||
| 25.02. | Moss Genomics Inc.: Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency | 118 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy... ► Artikel lesen | |
| MOSS GENOMICS Aktie jetzt für 0€ handeln | |||||
| 04.02. | Moss Genomics Inc.: Moss Genomics Announces Private Placement and Agreement to Acquire Ethereum | 514 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce a non-brokered private placement of up... ► Artikel lesen | |
| 01.02. | Moss Genomics Inc: Moss Genomics closes $250,000 private placement | 1 | Stockwatch | ||
| 01.02. | Moss Genomics Inc.: Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors | 957 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced... ► Artikel lesen | |
| 24.01. | Moss Genomics Inc: Moss to change business focus to ethereum | 2 | Stockwatch | ||
| 24.01. | Moss Genomics Inc.: Moss Genomics Provides Corporate Update and Announces Shift in Business Strategy | 756 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to provide an update on the Company's operations and... ► Artikel lesen | |
| 14.01. | Moss Genomics Inc. Announces Successful German Listing on the Frankfurt Stock Exchange (FSE) | 228 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to announce that it has successfully listed... ► Artikel lesen | |
| 14.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.01.2025 | 281 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2025
Aktien
1 CA61965T1012 Moss Genomics Inc.
2... ► Artikel lesen | |
| 24.12.24 | Moss Genomics Inc: Moss appoints Liu as CEO, director; to buy 160 ETH | 5 | Stockwatch | ||
| 24.12.24 | Moss Genomics Inc.: Canadian Company Moss Genomics Announces Agreement to Acquire Ethereum, Appoints Jack Liu as CEO and Director, Private Placement and Option Grant | 703 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 24, 2024) - Moss Genomics Inc. (CSE: MOSS) (the "Company" or "Moss") today announced the appointment of Jack Liu as CEO and a Director of the... ► Artikel lesen | |
| 18.07.24 | Moss Genomics Inc. Welcomes Martin Bajic to Its Board | 540 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 18, 2024) - Moss Genomics Inc. (CSE: MOSS) (the "Company" or "Moss") is pleased to announce that it has appointed Martin Bajic to its Board of Directors.... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,120 | +0,57 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| EVOTEC | 5,890 | -0,25 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| BIOVENTUS | 9,510 | 0,00 % | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen | |
| CG ONCOLOGY | 22,430 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| BIONTECH | 84,00 | -1,41 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| BB BIOTECH | 30,450 | -2,87 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| 89BIO | 7,190 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,760 | 0,00 % | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| DISC MEDICINE | 48,500 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive... ► Artikel lesen | |
| GUBRA | 58,00 | -3,33 % | AKTIONÄR-Depotwert Gubra: Im Sog von Novo Nordisk - Daten voraus | Die Aktie des dänischen Biopharma-Riesen Novo Nordisk fällt und fällt. Der Abverkauf geht auch an kleineren Playern im Adipositas-Bereich nicht spurlos vorbei. So auch beim AKTIONÄR-Depotwert Gubra:... ► Artikel lesen | |
| IMMUNOME | 6,710 | 0,00 % | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | ||
| 2SEVENTY BIO | 4,955 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| STRYKER | 332,20 | -4,49 % | Dividendenbekanntmachungen (31.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1847 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,187 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 4,425 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors | Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule... ► Artikel lesen | |
| AMGEN | 274,15 | -2,89 % | P/E Ratio Insights for Amgen |
Das Unternehmen MOSS GENOMICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +42,86 % bei einem Aktienkurs von 0,105 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOSS GENOMICS INC finden Sie auf Wallstreet Online.
